Acumen Pharmaceuticals ABOS

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.01 (+0.81%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Acumen Pharmaceuticals (ABOS)
    Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $1.25

    • Market Cap

      $75.10 Million

    • Price-Earnings Ratio

      -2.50

    • Total Outstanding Shares

      60.08 Million Shares

    • Total Employees

      52

    • Dividend

      No dividend

    • IPO Date

      July 1, 2021

    • SIC Description

      Biological Products, (no Disgnostic Substances)

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      427 park st., Charlottesville, VA, 22902

    • Homepage

      https://www.acumenpharm.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities$-24.60 Million
    Net Cash Flow From Investing Activities$-10.13 Million
    Net Cash Flow From Financing Activities$-42,000
    Net Cash Flow From Financing Activities, Continuing$-42,000
    Net Cash Flow From Investing Activities, Continuing$-10.13 Million
    Net Cash Flow, Continuing$-34.77 Million

    Income Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Income/Loss$-29.77 Million
    Revenues$0
    Income/Loss From Continuing Operations After Tax$-29.77 Million
    Diluted Average Shares$60.08 Million
    Income/Loss From Continuing Operations Before Tax$-29.77 Million
    Other Operating Expenses$5.02 Million

    Comprehensive Income

    July 1, 2024 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss Attributable To Parent$-29.08 Million
    Comprehensive Income/Loss$-29.08 Million
    Other Comprehensive Income/Loss$-29.08 Million

    Balance Sheet

    July 1, 2024 to September 30, 2024
    MetricValue
    Accounts Payable$2.34 Million
    Current Liabilities$19.91 Million
    Current Assets$207.63 Million
    Noncurrent Assets$59.34 Million
    Fixed Assets$89,000
    Other Non-current Liabilities$185,000

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ABOS from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.